Select Publications
Ariazi EA et al. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 2006;6(3):181-202. Abstract
Armstrong T et al. Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 2005;32(2):305-11. Abstract
Bardou VJ et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21(10):1973-9. Abstract
Bria E et al. Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: Pooled-analysis of 8794 patients. Cancer Treat Rev 2006;32(5):325-32. Abstract
Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004;9(Suppl 3):10-5. Abstract
Buzdar AU, Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: Emerging data. Clin Cancer Res 2006;12(3 Pt 2):1037s-48s. Abstract
Carlson RW et al. HER2 testing in breast cancer: NCCN HER2 Testing in Breast Cancer Task Force. J Natl Compr Canc Netw 2006;4(Suppl 3):1-22. Abstract
Cuzick J et al. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006;94(4):460-4. Abstract
Ewer MS et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23(31):7820-6. Abstract
Forbes JF. The use of early adjuvant aromatase inhibitor therapy: Contributions from the BIG 1-98 letrozole trial. Semin Oncol 2006;33(2 Suppl 7):2-7. Abstract
Gelmon K et al. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist 2006;11(Suppl 1):42-51. Abstract
Goldstein LJ. Controversies in adjuvant endocrine treatment of premenopausal women. Clin Breast Cancer 2006;6(Suppl 2):36-40. Abstract
Goss PE. Preventing relapse beyond 5 years: The MA.17 extended adjuvant trial. Semin Oncol 2006;33(2 Suppl 7):8-12. Abstract
Gradishar WJ. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother 2006;7(8):1041-53. Abstract
Gradishar WJ. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology 2005;69(1):1-9. Abstract
Jackisch C. HER-2-positive metastatic breast cancer: Optimizing trastuzumab-based therapy. Oncologist 2006;11(Suppl 1):34-41. Abstract
Joensuu H et al. Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract
Jones SE et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23(24):5542-51. Abstract
Mandelblat J et al. Capecitabine-docetaxel combination treatment. Expert Rev Anticancer Ther 2006;6(9):1169-78. Abstract
Meric-Bernstam F, Hung MC. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 2006;12(21):6326-30. Abstract
Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract
Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial conducted by the Eastern Cooperative Oncology Group (E2100). Presentation. San Antonio Breast Cancer Symposium 2005b;Abstract 3.
Morabito A et al. Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. Oncol Rep 2006;16(2):393-8. Abstract
Morales L et al. Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting. Curr Opin Oncol 2005;17(6):559-65. Abstract
Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34. Abstract
Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26. Abstract
Paik S. et al. Real-world performance of HER2 testing — National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94(11):852-4. Abstract
Parrish MM, Adams S. An exploratory qualitative analysis of the emotional impact of breast cancer and caregiving among older women. Care Manag J 2003;4(4):191-7. Abstract
Perez E, Muss HB. Optimizing adjuvant chemotherapy in early-stage breast cancer. Oncology (Williston Park) 2005;19(14):1759-67. Abstract
Perez EA et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24(19):3032-8. Abstract
Siminoff LA et al. A decision aid to assist in adjuvant therapy choices for breast cancer. Psychooncology 2006;15(11):1001-13. Abstract
Thuerlimann B et al. Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: Past, present and future recommendations. Eur J Cancer 2006. Abstract
Wickerham DL. The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study. ASCO 2006;Abstract LBA5.
Wirk B, Perez E. Role of gemcitabine in breast cancer management: An update. Semin Oncol 2006;33(1 Suppl 2):6-14. Abstract
